Adjuvant chemotherapy of superficial transitional cell bladder carcinoma: preliminary results of a European organization for research on treatment of cancer. Randomized trial comparing doxorubicin hydrochloride, ethoglucid and transurethral resection alone.
Patients with superficial transitional cell carcinoma of the bladder were entered in a randomized clinical trial to compare the efficacies of transurethral resection alone or followed by bladder instillation of doxorubicin hydrochloride or ethoglucid (Epodyl) for 1 year. Results showed that adjuvant chemotherapy with the selected drugs prolonged the mean interval between recurrences. Mild systemic toxicity and chemical cystitis were observed in 3 and 3 per cent, respectively, of the patients given ethoglucid, and in 5 and 4 per cent, respectively, of those taking doxorubicin.
D002295:Carcinoma, Transitional Cell / Q000188:drug therapy* / Q000601:surgery*; D002986:Clinical Trials as Topic; D003131:Combined Modality Therapy; D004317:Doxorubicin / Q000009:adverse effects / Q000627:therapeutic use*; D004987:Ethers / Q000627:therapeutic use*; D005009:Ethoglucid / Q000009:adverse effects / Q000627:therapeutic use*; D006801:Humans; D008297:Male; D008722:Methods; D009364:Neoplasm Recurrence, Local; D011897:Random Allocation; D014521:Urethra; D001749:Urinary Bladder Neoplasms / Q000188:drug therapy* / Q000601:surgery*
D004987:Ethers; D005009:Ethoglucid; D004317:Doxorubicin